Compounds with structural similarities to the neurotransmitter (acetylcholine) are mostly used to inhibit the activity of acetylcholinesterase (AChE) in Alzheimer’s disease (AD) therapy. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.